文献速递膀胱癌与上尿路尿路上皮癌

非肌层浸润性膀胱癌T1亚分期与卡介苗治疗失败相关并改善诊断时患者分层

T1 Substaging of Nonmuscle Invasive Bladder Cancer is Associated with bacillus Calmette-Guérin Failure and Improves Patient Stratification at Diagnosis.
PubMed 文献 · J Urol · 2020-11-16

本研究纳入264例接受≥5次卡介苗诱导灌注的原发性高危非肌层浸润性膀胱癌伴固有层浸润患者,中央病理 review 行T1亚分期(微浸润 vs 广泛浸润)。中位随访68个月,广泛浸润组卡介苗失败率41% vs 微浸润组21%(p=0.002),3年高级别无复发生存率64% vs 83%(p=0.004);T1亚分期是高级别无复发生存(HR 3.2,p=0.005)和无进展生存(HR 3.0,p=0.009)的独立预测因子。

要点

  • T1亚分期可区分卡介苗治疗失败风险:广泛浸润失败率41%,微浸润21%。
  • 广泛浸润是高级别无复发生存(HR 3.2)和无进展生存(HR 3.0)的独立预测因子。
  • 最高危/微浸润患者无进展生存优于最高危/T1e患者(p.adj=0.038)。

核心结论

  • T1亚分期为接受卡介苗治疗的原发性高危非肌层浸润性膀胱癌患者提供重要预后信息,广泛浸润者卡介苗失败风险更高。
  • T1高危非肌层浸润性膀胱癌亚分期有潜力在诊断时指导选择卡介苗或替代策略。

研究设计与样本

  • 纳入接受≥5次卡介苗诱导灌注的原发性高危非肌层浸润性膀胱癌患者,共264例伴固有层浸润。
  • 所有肿瘤经中央病理 review 行T1亚分期(微浸润 vs 广泛浸润),并按主要泌尿外科指南分为高危/最高危亚组。
  • 主要终点为卡介苗失败(定义为发生高级别复发),次要终点为高级别无复发生存和無进展生存,采用时间-事件分析。

主要发现

  • 264例中73%为广泛浸润,27%为微浸润;中位随访68个月(IQR 43-98)。
  • 卡介苗失败在广泛浸润 vs 微浸润肿瘤中更常见(41% vs 21%,p=0.002)。
  • 3年高级别无复发生存(定义为卡介苗失败)广泛浸润 vs 微浸润为64% vs 83%(p=0.004)。
  • 多变量分析中T1亚分期是高级别无复发生存的独立预测因子(HR 3.2,p=0.005)和无进展生存的独立预测因子(HR 3.0,p=0.009)。
  • 最高危/微浸润疾病较最高危/T1e疾病无进展生存改善(p.adj=0.038)。

临床怎么用

  • 对原发性高危T1非肌层浸润性膀胱癌,诊断时行T1亚分期(微浸润 vs 广泛浸润)有助于识别卡介苗失败高危患者。
  • 广泛浸润患者卡介苗失败风险较高,可考虑更密切监测或早期讨论替代治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Currently, markers are lacking that can identify patients with high risk nonmuscle invasive bladder cancer who will fail bacillus Calmette-Guérin treatment. Therefore, we evaluated the prognostic value of T1 substaging in patients with primary high risk nonmuscle invasive bladder cancer. MATERIALS AND METHODS: Patients with primary high risk nonmuscle invasive bladder cancer who received ≥5 bacillus Calmette-Guérin induction instillations were included. All tumors were centrally reviewed, which included T1 substaging (microinvasion vs extensive invasion of the lamina propria). T1 patients were stratified into high risk or highest risk subgroups according to major urology guidelines. Primary end point was bacillus Calmette-Guérin failure, defined as development of a high grade recurrence. Secondary end points were high grade recurrence-free survival, defined as time from primary diagnosis to biopsy-proven high grade recurrence and progression-free survival. Time-to-event analyses were used to predict survival. RESULTS: A total of 264 patients with high risk nonmuscle invasive bladder cancer had tumor invasion of the lamina propria, of which 73% were classified as extensive invasion and 27% as microinvasion. Median followup was 68 months (IQR 43-98) and bacillus Calmette-Guérin failure was more common among patients with extensive vs microinvasive tumors (41% vs 21%, p=0.002). The 3-year high grade recurrence-free survival (defined as bacillus Calmette-Guerin failure) for patients with extensive vs microinvasive tumors was 64% vs 83% (p=0.004). In multivariate analysis, T1 substaging was an independent predictor of high grade recurrence-free survival (HR 3.2, p=0.005) and progression-free survival (HR 3.0, p=0.009). Patients with highest risk/microinvasive disease have an improved progression-free survival as compared to highest risk/T1e disease (p.adj=0.038). CONCLUSIONS: T1 substaging provides important prognostic information on patients with primary high risk nonmuscle invasive bladder cancer treated with bacillus Calmette-Guérin. The risk of bacillus Calmette-Guérin failure is higher in extensive vs microinvasive tumors. Substaging of T1 high risk nonmuscle invasive bladder cancer has the potential to guide treatment decisions on bacillus Calmette-Guérin vs alternative strategies at diagnosis.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. de Jong FC, Hoedemaeker RF, Kvikstad V, et al. T1 Substaging of Nonmuscle Invasive Bladder Cancer is Associated with bacillus Calmette-Guérin Failure and Improves Patient Stratification at Diagnosis. J Urol. 2020. PMID: 33191862. doi:10.1097/JU.0000000000001422

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。